Influence of Beer on Gut Microbiota and Biochemical Outcomes: Alcohol Impact.
Not Applicable
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Dietary Supplement: Beer with 5.20 % alcoholDietary Supplement: Non-alcoholic beer with 0.45 % alcoholDietary Supplement: Non-alcoholic beer with 0.00 % alcohol
- Registration Number
- NCT03513432
- Lead Sponsor
- Universidade do Porto
- Brief Summary
Our aim is to assess the effects of moderate consumption of beer and non-alcoholic beer on gut microbiota and biochemical biomarkers in healthy adults.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 30
Inclusion Criteria
- Adult men (18-65 years);
- Healthy volunteers free of chronic diseases with relevant effect on gastrointestinal system;
- Without a diagnosis of any digestive disease including functional bowel disorders such as IBS;
- Moderate alcohol consumers;
- Willing and able to provide written informed consent.
Exclusion Criteria
- Documented cardiovascular disease (ischaemic heart disease - angina or recent or old myocardial infarction or previous or cerebral vascular accident, peripheral vascular disease);
- With diabetes or other relevant metabolic diseases;
- With any known infectious diseases, namely infections with HIV, Hepatitis B or C virus;
- Intake of antibiotics in the last 4 weeks and laxatives in the last 2 weeks;
- Subjects with history of drug, alcohol or other substances abuse.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Beer with 5.20 % alcohol Beer with 5.20 % alcohol 330 ml beer (5.20 % alcohol)/day Non-alcoholic beer with 0.45 % alcohol Non-alcoholic beer with 0.45 % alcohol 330 ml non-alcoholic beer (0.45 % alcohol)/day Non-alcoholic beer with 0.00 % alcohol Non-alcoholic beer with 0.00 % alcohol 330 ml non-alcoholic beer (0.00 % alcohol)/day
- Primary Outcome Measures
Name Time Method Changes in intestinal microbiota from baseline at visit 1 (after 1-week run-in period) and at visit 2 (after 4-week intake period)
- Secondary Outcome Measures
Name Time Method Changes in fasting serum triglycerides from baseline at visit 1 (after 1-week run-in period) and at visit 2 (after 4-week intake period) Changes in fasting serum cHDL from baseline at visit 1 (after 1-week run-in period) and at visit 2 (after 4-week intake period) Changes in Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) from baseline at visit 1 (after 1-week run-in period) and at visit 2 (after 4-week intake period) Changes in fasting serum total cholesterol from baseline at visit 1 (after 1-week run-in period) and at visit 2 (after 4-week intake period) Changes in fasting serum cLDL from baseline at visit 1 (after 1-week run-in period) and at visit 2 (after 4-week intake period) Changes in fasting serum LPS levels from baseline at visit 1 (after 1-week run-in period) and at visit 2 (after 4-week intake period) Changes in body mass index from baseline at visit 1 (after 1-week run-in period) and at visit 2 (after 4-week intake period) Weight and height will be combined to report BMI in kg/m\^2.
Changes in total body fat mass from baseline at visit 1 (after 1-week run-in period) and at visit 2 (after 4-week intake period)
Trial Locations
- Locations (1)
Faculdade de Ciências Médicas da Universidade NOVA de Lisboa
🇵🇹Lisboa, Portugal